{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-023045","form_type":"8-K","ticker":"SNDX","cik":"0001395937","company_name":"Syndax Pharmaceuticals Inc","filed_at":"2022-06-13T23:59:59+00:00","discovered_at":"2026-05-14T18:04:00.464121+00:00","generated_at":"2026-06-25T02:17:30.207762+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Syndax appoints Keith A. Goldan as CFO; base salary $450k, option for 230k shares","bullets":["Keith Goldan appointed CFO effective June 13, 2022; previously CFO at OptiNose.","Employment terms: $450k base salary, 40% target bonus, option for 230k shares (4-yr vest), $50k RSU sign-on.","Sharon Klahre named VP, Investor Relations and Communications, reporting to Goldan.","Goldan brings ~30 years biopharma CFO experience; co. expects multiple pivotal readouts in 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-023045","json":"https://secwatch.observer/filing/0001564590-22-023045.json","markdown":"https://secwatch.observer/filing/0001564590-22-023045.md","text":"https://secwatch.observer/filing/0001564590-22-023045.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1395937/000156459022023045/0001564590-22-023045-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1395937/000156459022023045/sndx-8k_20220608.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T02:17:30.207762+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"94f54a2ae3","claim":"Keith A. Goldan was appointed as Chief Financial Officer at Syndax Pharmaceuticals Inc.","evidence_excerpt":"On June 13, 2022, Syndax Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing that Keith A. Goldan will join the Company as Chief Financial Officer, effective June 13, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1395937/000156459022023045/0001564590-22-023045-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}